Longitudinal Patient-Reported Outcome Trajectories in Long COVID: Findings From the STOP-PASC Clinical Trial
Distinct PRO trajectories reflect the clinical heterogeneity of Long COVID. NMV/r showed no clear benefit across subgroups. These findings emphasize the need for validated, Long COVID-specific PRO instruments and targeted therapeutic trials tailored to Long COVID subtypes.
Authors
- Haley Hedlin (ORCID: https://orcid.org/0000-0002-0757-7959)
- Paul J. Utz (ORCID: https://orcid.org/0000-0003-1181-1565)
- Prasanna Jagannathan (ORCID: https://orcid.org/0000-0001-6305-758X)
- Evan Maestri (ORCID: https://orcid.org/0000-0003-4829-1444)
- Jane W. Liang (ORCID: https://orcid.org/0000-0002-2302-3809)
- Michelle I. Lin (ORCID: https://orcid.org/0000-0003-2824-0893)
- Blake Shaw (ORCID: https://orcid.org/0000-0002-0640-8985)
- Hector Fabio Bonilla (ORCID: https://orcid.org/0000-0002-0513-8733)
- Upinder Singh (ORCID: https://orcid.org/0000-0003-0630-0306)
- Linda N. Geng (ORCID: https://orcid.org/0000-0002-9891-5705)
Institutions
- University of Iowa (US)
- Kaiser Permanente (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1093/ofid/ofaf634
- Citations
- 1
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Pfizer
- National Institutes of Health
- Stanford Bio-X
- National Center for Research Resources
- National Center for Advancing Translational Sciences